论文部分内容阅读
由于肿瘤的发生是一个复杂的生物学过程,再加上肿瘤患者存在的个体差异,药物转运蛋白的基因多态性导致的化疗疗效和不良反应显著差异越来越受到人们的重视。多西他赛作为多种肿瘤的有效治疗药物,其存在的疗效、不良反应差异与基因多态性的关系也日益受到人们的关注,其中研究最多的主要是ABCB1的基因多态性。我们就ABCB1的基因多态性情况,ABCB1基因多态性对多西他赛药动学的影响,ABCB1基因多态性与多西他赛疗效、不良反应的相关性几个方面进行综述,以期为临床更合理地运用多西他赛,发挥更有效地抗肿瘤作用并减少不良反应提供参考。
As the occurrence of tumors is a complex biological process, coupled with the individual differences existing in cancer patients, the significant differences between chemotherapy and adverse reactions caused by the gene polymorphisms of drug transporters have drawn more and more attention. Docetaxel as a variety of effective treatment of cancer, its existing efficacy, differences in adverse reactions and genetic polymorphisms are also increasingly concerned about the people, the most studied mainly ABCB1 gene polymorphisms. We reviewed the genetic polymorphism of ABCB1, the influence of polymorphism of ABCB1 gene on the pharmacokinetics of docetaxel, the relationship between ABCB1 gene polymorphism and the efficacy of docetaxel, and the adverse reactions. To make a more rational clinical use of docetaxel, to play a more effective anti-tumor effect and reduce adverse reactions provide a reference.